Singapore, June 2 -- Biond Biologics, a private clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases, and the Guangzhou-Israel Biotechnology Fund (GIBF), a leading life science investment fund, have announced a strategic $8 million investment together with the formation of a China-based joint venture to advance Biond's innovative oncology pipeline.

The newly established joint venture will focus on accelerating the development of Biond's lead programmes, including BND-67, a first-in-class therapy targeting CD28 shedding, as well as BND-22, a Phase 2 anti-ILT2 antibody and additional pipeline assets.

The collaboration is designed to leverage Biond's differentiated oncology ...